Physician profile
Oscar Rivera
NPI 1376728279
$2,871.34
in general payments reported to CMS, 2019-2025
32 companies · $83.53 in 2025
The $83.53 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $31.23 · 2021: $228 · 2022: $964 · 2023: $424 · 2024: $93.31 · 2025: $83.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $417.17 | 2021-2025 | Impella |
| Abbott Laboratories | $340.01 | 2019-2023 | Pressurewire |
| Janssen Pharmaceuticals, INC | $319.40 | 2019-2023 | Xarelto |
| Penumbra, INC. | $256.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $208.58 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $178.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.61 | 2019-2023 | Lifevest |
| Impulse Dynamics (USA) INC. | $143.56 | 2022 | |
| Cardiovascular Systems INC. | $124.40 | 2019-2022 | |
| Shockwave Medical, INC | $74.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $61.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $57.44 | 2022-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $56.15 | 2019-2022 | |
| Acist Medical Systems, INC. | $51.63 | 2022 | |
| Irhythm Technologies, INC. | $45.43 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $44.38 | 2019 | |
| Amgen INC. | $37.91 | 2019 | |
| Esperion Therapeutics, INC. | $31.32 | 2021-2022 | |
| Pfizer INC. | $29.70 | 2019-2022 | |
| Biotronik INC. | $28.23 | 2024 | Biomonitor |
| United Therapeutics Corporation | $25.00 | 2019 | |
| Lilly USA, LLC | $24.91 | 2023 | Mounjaro |
| Pbg Puerto Rico LLC | $18.50 | 2019 | |
| Itamar Medical INC | $17.07 | 2022 | |
| Imperative Care, INC | $16.90 | 2025 | Symphony Catheter |
| Lundbeck LLC | $15.69 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.06 | 2023 | Definity |
| Tactile Systems Technology INC | $14.46 | 2019 | |
| Ethicon US, LLC | $14.12 | 2022 | |
| Novo Nordisk INC | $13.22 | 2021 | |
| Angiodynamics, INC. | $12.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.